Manulife (Manufacturers Life Insurance)
ADCT icon

Manulife (Manufacturers Life Insurance)’s ADC Therapeutics ADCT Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$96.8K Buy
25,826
+1,068
+4% +$4.21K ﹤0.01% 2630
2025
Q4 		$87.4K Buy
24,758
+1,623
+7% +$6.59K ﹤0.01% 2733
2025
Q3 		$92.5K Sell
23,135
-2,605
-10% -$8.21K ﹤0.01% 2795
2025
Q2 		$69K Sell
25,740
-3,955
-13% -$8.32K ﹤0.01% 2837
2025
Q1 		$41.9K Buy
29,695
+1,107
+4% +$1.88K ﹤0.01% 2851
2024
Q4 		$56.9K Buy
28,588
+2,757
+11% +$7.21K ﹤0.01% 2923
2024
Q3 		$81.4K Sell
25,831
-1,107
-4% -$3.49K ﹤0.01% 2910
2024
Q2 		$85.1K Buy
+26,938
New +$107K ﹤0.01% 2864
2023
Q3 		– Sell
-146,566
Closed -$315K – 2975
2023
Q2 		$315K Hold
146,566
– – ﹤0.01% 2325
2023
Q1 		$286K Buy
146,566
+68,821
+89% +$254K ﹤0.01% 2331
2022
Q4 		$295K Hold
77,745
– – ﹤0.01% 2320
2022
Q3 		$380K Hold
77,745
– – ﹤0.01% 2150
2022
Q2 		$606K Buy
77,745
+13,343
+21% +$126K ﹤0.01% 1911
2022
Q1 		$952K Buy
+64,402
New +$1.02M ﹤0.01% 1784

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s ADCT Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) increased its ADC Therapeutics (ADCT) stake by 4.3% in Q1 2026, buying an estimated $4.21K and bringing the position to 25,826 shares worth $96.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2630.

Manulife (Manufacturers Life Insurance) first reported a position in ADCT in Q1 2022 and has held it in 14 quarters since. The position peaked at $952K in Q1 2022. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) held 25,826 shares of ADC Therapeutics worth $96.8K as of Q1 2026.
  • Manulife (Manufacturers Life Insurance) bought 1,068 ADC Therapeutics shares in Q1 2026, an estimated $4.21K.
  • ADC Therapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #2630 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in ADC Therapeutics in Q1 2022 and has held it in 14 quarters since.
  • Manulife (Manufacturers Life Insurance)'s ADC Therapeutics position peaked at $952K in Q1 2022.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.